Literature DB >> 15087601

Atrial fibrillation and hypercoagulability: dependent on clinical factors or/and on genetic alterations?

Eleni Hatzinikolaou-Kotsakou1, Zarifis Kartasis, Dimitrios Tziakas, Athanasios Hotidis, Dimitrios Stakos, Konstantinos Tsatalas, Georgios Bourikas, Maria E Kotsakou, Dimitrios I Hatseras.   

Abstract

UNLABELLED: It is well known that atrial fibrillation is associated with high incidence of thromboembolic events, propably due to a prothrombotic or hypercoagulable state. However, it is unclear whether or not there is any difference of this prothrombotic state in the clinical subgroups of atrial fibrillation patients, that is, in those with paroxysmal, persistent or permanent atrial fibrillation. From the other side the role of the arrhythmia duration on the changes of coagulative variables in atrial fibrillation patients is not clearly enough. The contribution of genetic and functional alterations in factors of the coagulation and fibrinolytic pathways (that is hemostatic risk factors) to the development of hypercoagulation state in atrial fibrillation requires clarification. We investigated therefore (1) if there are differences in the prothrombotic state between patients with different clinical status of the arrhythmia, (2) if the arrhythmia duration per se could be an independent determinant of the prothrombotic state in all atrial fibrillation patients and (3) if coexistent genetic alterations in haemostatic risk factors in patients with atrial fibrillation could contribute to the development of prothrombotic abnormalities.
METHODS: Over a period of 23 months, we studied 55 patients with chronic non-valvular atrial fibrillation. We recruited 18 consecutive patients (13 men, mean age 59 +/- 10 years) with paroxysmal atrial fibrillation 17 patients (11 men, mean age 61 +/- 7 years) with persistent atrial fibrillation who underwent elective successful DC and remained in sinus rhythm at the 3 month visit and 20 patients (14 men mean age 64 +/- 9) with permanent atrial fibrillation. Blood results were compared to 17 age-sex- and race-matched controls. The prothrombotic state was quantified by measurement of plasma levels of fibrinogen, soluble P -selectin (an index of platelet activation) and von Willebrand factor (a marker of endothelial dysfunction). We assessed the frequencies of factor V Leiden and prothrombin variant G20210A to determine whether particular inherited haemostatic risk factors may have contribution to the development of prothrombotic state in atrial fibrillation patients.
RESULTS: Permanent atrial fibrillation was associated with significant raised levels of von Willebrand factor, fibrinogen levels and soluble P -selectin compared to matched controls (all p < 0.001) and matched patients with paroxysmal and permanent AF (all p ranged between <0.003 and <0.002). Patients with persistent atrial fibrillation had significantly elevated von Willebrand factor levels (p = 0.0064) and fibrinogen levels (p = 0.002), but not Soluble P -selectin (p = 0.509). when compared to controls. Patients with paroxysmal atrial fibrillation had significantly elevated levels of P -selectin (p = 0.005) and fibrinogen (p = 0.003), but not von Willebrand factor (p =.0.61) compared to controls. Stepwise multiple regression analyses demonstrated that the arrhythmia duration (approximately 3 years) was an independent predictor of abnormal von Willebrand factor, fibrinogen and soluble P -selectin levels. Restoration of sinus rhythm in paroxysmal atrial fibrillation subgroup and successful electrical cardioversion of patients with permanent fibrillation atrial fibrillation did not significantly alter levels of the affected factors. The frequency of factor V Leiden was 8.9 in all studied patients with atrial fibrillation, versus 2.4% in the control group (odds ratio [OR] 4.6 [95% confidence (CI) 1.4-17.5], p = 0.02). The frequency of the prothrombin variant G20210A was 6.4.% compared with control group 1.6% (OR 4.9 [95% confidence interval (CI) 1.2-2.9], p = 0.04). There was a trend towards an increased frequency of factor V Leiden and/or prothrombin variant G20210A in patients age <55 years and in patients living at a particular area of Thrace mountains.
CONCLUSIONS: Our results showed that there were significant differences in the prothrombotic state when patients with paroxysmal, and persistent atrial fibrillation were compared to matched that there were significant differences in the prothrombotic state when patients with paroxysmal, and persistent atrial fibrillation were compared to matched patients with permanent atrial fibrillation and controls in sinus rhythm. The duration of the arrhythmia (about 3 years) was an independent predictor of abnormal measured factors. We found for the first time that some genetic alterations in haemostatic risk factors could be coexist in atrial fibrillation patients and may be a contributor to the development of hypercoagulability in atrial fibrillation patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15087601     DOI: 10.1023/B:THRO.0000024053.45693.fc

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  19 in total

1.  Geographic distribution of the 20210 G to A prothrombin variant.

Authors:  F R Rosendaal; C J Doggen; A Zivelin; V R Arruda; M Aiach; D S Siscovick; A Hillarp; H H Watzke; F Bernardi; A M Cumming; F E Preston; P H Reitsma
Journal:  Thromb Haemost       Date:  1998-04       Impact factor: 5.249

Review 2.  Hypothesis: is soluble P-selectin a new marker of platelet activation?

Authors:  A D Blann; G Y Lip
Journal:  Atherosclerosis       Date:  1997-02-10       Impact factor: 5.162

3.  Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis.

Authors:  G Y Lip; G D Lowe; A Rumley; F G Dunn
Journal:  Am Heart J       Date:  1996-04       Impact factor: 4.749

4.  Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation.

Authors:  H Sohara; S Amitani; M Kurose; K Miyahara
Journal:  J Am Coll Cardiol       Date:  1997-01       Impact factor: 24.094

5.  World distribution of factor V Leiden.

Authors:  D C Rees; M Cox; J B Clegg
Journal:  Lancet       Date:  1995-10-28       Impact factor: 79.321

6.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction.

Authors:  P M Ridker; D E Vaughan; M J Stampfer; J E Manson; C H Hennekens
Journal:  Lancet       Date:  1993-05-08       Impact factor: 79.321

7.  Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study.

Authors:  P A Wolf; T R Dawber; H E Thomas; W B Kannel
Journal:  Neurology       Date:  1978-10       Impact factor: 9.910

Review 8.  The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications.

Authors:  A D Blann; G Y Lip
Journal:  Blood Coagul Fibrinolysis       Date:  1998-06       Impact factor: 1.276

9.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.

Authors:  T Koster; F R Rosendaal; H de Ronde; E Briët; J P Vandenbroucke; R M Bertina
Journal:  Lancet       Date:  1993 Dec 18-25       Impact factor: 79.321

10.  Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.

Authors:  G Y Lip; G D Lowe; A Rumley; F G Dunn
Journal:  Br Heart J       Date:  1995-06
View more
  13 in total

Review 1.  Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2005-02       Impact factor: 2.300

2.  A clinical cardiology perspective of thrombophilias.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

3.  Alternative presentation of tako-tsubo syndrome with spontaneous echo-contrast and "onion" shaped apical ballooning.

Authors:  Natale Daniele Brunetti; Riccardo Ieva; Michele Correale; Luisa De Gennaro; Pier Luigi Pellegrino; Ezio Dioguardi; Matteo Di Biase
Journal:  J Thromb Thrombolysis       Date:  2008-11-08       Impact factor: 2.300

4.  Advanced age, low left atrial appendage velocity, and factor V promoter sequence variation as predictors of left atrial thrombosis in patients with nonvalvular atrial fibrillation.

Authors:  Dmitry A Zateyshchikov; Alexey N Brovkin; Dimitry A Chistiakov; Valery V Nosikov
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

5.  Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation.

Authors:  Albert Yuh-Jer Shen; Wansu Chen; Janis F Yao; Somjot S Brar; Xunzhang Wang; Alan S Go
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 6.  Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate.

Authors:  Jeffrey J Goldberger; Rishi Arora; David Green; Philip Greenland; Daniel C Lee; Donald M Lloyd-Jones; Michael Markl; Jason Ng; Sanjiv J Shah
Journal:  Circulation       Date:  2015-07-28       Impact factor: 29.690

7.  Association of hemostatic markers with atrial fibrillation: a meta-analysis and meta-regression.

Authors:  Na Wu; Shifei Tong; Ying Xiang; Long Wu; Bin Xu; Yao Zhang; Xiangyu Ma; Yafei Li; Zhiyuan Song; Li Zhong
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

8.  Early Changes in the Antithrombin and Thrombin-Antithrombin Complex in Patients With Paroxysmal Atrial Fibrillation.

Authors:  Mariya Negreva; Svetoslav Georgiev; Krasimira Prodanova; Julia Nikolova
Journal:  Cardiol Res       Date:  2016-06-24

Review 9.  Predictive Role of Coagulation, Fibrinolytic, and Endothelial Markers in Patients with Atrial Fibrillation, Stroke, and Thromboembolism: A Meta-Analysis, Meta-Regression, and Systematic Review.

Authors:  Alexander Weymann; Anton Sabashnikov; Sadeq Ali-Hasan-Al-Saegh; Aron-Frederik Popov; Seyed Jalil Mirhosseini; William L Baker; Mohammadreza Lotfaliani; Tong Liu; Hamidreza Dehghan; Senol Yavuz; Michel Pompeu Barros de Oliveira Sá; Jae-Sik Jang; Mohamed Zeriouh; Lei Meng; Fabrizio D'Ascenzo; Abhishek J Deshmukh; Guiseppe Biondi-Zoccai; Pascal M Dohmen; Hugh Calkins; Integrated Meta-Analysis Of Cardiac Cardiac Surgery And Cardiology-Group Imcsc-Group
Journal:  Med Sci Monit Basic Res       Date:  2017-03-31

10.  Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation.

Authors:  Noémi Klára Tóth; Zoltán Csanádi; Orsolya Hajas; Alexandra Kiss; Edina Nagy-Baló; Kitti Bernadett Kovács; Ferenc Sarkady; László Muszbek; Zsuzsanna Bereczky; László Csiba; Zsuzsa Bagoly
Journal:  Biomed Res Int       Date:  2017-06-21       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.